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Background: We evaluated the outcomes of secondary procedures
after endovascular aneurysm repair (EVAR).
Methods: From 2002 to 2008, 1450 patients underwent EVAR and
were evaluated by computed tomography angiography (CTA) every 6 to 12
months. Patients with type I and III endoleaks, unexplained endotension,
limb occlusion, stent graft migration with and without type I endoleak, and
aneurysm rupture underwent secondary interventions. Type II endoleaks at
6 months without a decrease in the aneurysm sac underwent translumbar
embolization. Data were prospectively collected.
Results: After 1450 EVAR procedures, 1362 elective (94%) and 88
emergency (6%), 259 patients (17.9%) required additional procedures dur-
ing a mean follow-up of 32 months (range, 1-84 months). Of these, 229
(15.8%) required secondary procedures consisting of 200 endovascular
(87%) and 29 open surgical procedures (13%; Table). Of 29 patients with
aneurysm rupture, 22 (76%) were considered lost to follow-up after the
initial EVAR. An additional 30 patients (2.1%) required tertiary procedures,
including repeat translumbar embolization in 12 (0.8%), repeat proximal
stent graft extension for migration in 11 (0.8%), and elective open surgical
repair in 7 (0.5%). The overall mortality of these second and third proce-
dures was 3.9% and was highest in the aneurysm rupture group at 15% (4 of
29 patients; Table).
Conclusions: Our midterm experience indicates that 18% of patients
require additional secondary and tertiary procedures. Almost all of these
patients can be managed by endovascular means, with acceptable overall
mortality of 3.9%. Most type I endoleaks can be successfully treated by
translumbar embolization. Most patients with delayed aneurysm rupture
after EVAR can be successfully managed by endovascular or open surgical
repair.
Table. Midterm outcomes of secondary procedures after
endovascular aneurysm repair
Indication No. (%) Secondary procedures No. (%) Death No. (%)
Endoleak
Type I 39 (2.7) Proximal SG extension 14 (36) 2 (5)
TL embo 17 (44)
Spontaneous seal 6 (15)
Open surgical repair 2 (5)
Type II 104 (7.1) TL embo 98 (94) 2 (2)
Transfemoral embo 6 (6)
Type III 3 (0.2) SG extension 3 (100) -
Endotension 12 (0.8) SG relining 8 (67) -
Open surgical repair 2 (17)
No treatment 2 (17)
Limb thrombosis 14 (1) Fem-fem bypass 7 (50) 1 (7)
SG thrombectomy 5 (36)
No treatment 2 (14)
Migration 38 (2.6) SG extension 28 (74) 1 (3)
AUI 10 (36)
Rupture 29 (2.0) Open surgical repair 15 (52) 4 (15)
EVAR 13 (45)
Refused treatment 1 (3)
AUI, aortouniiliac, EVAR, endovascular aneurysm repair; SG, stent graft;
TL, translumbar.
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Background: This study identified risk factors for late mortality after
thoracic endovascular aortic repair (TEVAR).
Methods: A retrospective analysis of a prospectively maintained data-
base of consecutive TEVAR was conducted. Thirty-day and late survival was
determined by medical record review, telephone contact, or query of the
Social Security Death Index. Late mortality was assessed with respect to
patient characteristics at the time of initial treatment (ages, gender, pulmo-
nary, cardiac and renal disease, hypertension, hyperlipidemia, diabetes,
medication) preoperative laboratory values (albumin, hemoglobin, whiteblood cell [WBC] count, platelet count, creatinine), pathology (aneurysm
type, diameter), clinical presentation (symptomatic, rupture), and treatment
adjuncts (debranching). Variables significant by univariate analysis were
entered into a multivariate Cox regression model to ascertain independent
predictors of mortality.
Results: From 1998 and 2009, 252 patients (149men; median age, 70
years) underwent TEVAR. Indications were degenerative thoracic aortic
aneurysm (TAA) in 143, type B dissection in 62, mycotic aneurysm in 13,
traumatic disruption in 12, penetrating ulcer/intramural hematoma in 10,
anastomotic pseudoaneurysm in 4, or other pathology in 8. The 30-day
mortality was 9.5%, with stroke or spinal cord injury in 5.6%. Mean  SD
follow-up was 22  22 months, with a Kaplan-Meier mean survival of 53
months. Predominant causes of late death were cardiac disease, malignancy,
and chronic obstructive pulmonary disease (COPD). Predictors of late death
by univariate analysis included age (P  .01), cardiac arrhythmia (P  .03),
COPD (P .05), hyperlipidemia (P .03), statin use (P .02), aneurysm
diameter (P  .01), rupture, and elevated creatinine (P  01). Multivariate
analysis revealed that rupture (hazard ratio [HR] 3.1; 95% confidence
interval [CI], 1.02-9.44; P  03), debranching (HR, 2.20; 95% CI, 1.09-
4.24; P .03), preoperativeWBC count (HR, 1.23; 95%CI 1.09-1.39; P
.001), and aneurysm diameter (HR, 1.02; 95% CI 1.01-1.03; P .04) were
independent predictors of late mortality. Subgroup analysis of patients
undergoing elective TEVAR for asymptomatic, nonruptured TAA demon-
strated that debranching (HR, 2.47; 95% CI, 1.13-5.39; P  .02), WBC
count (HR, 1.19; 95% CI, 1.01-1.40; P  .04), and aneurysm diameter
(HR, 1.03; 95% CI 1.01-1.05; P .01) remain independently predictive of
late mortality (Fig 1).
Conclusions: Despite adequate initial repair, long-term survival after
TEVAR remains compromised. Concurrent debranching, preoperative
WBC count, and aneurysm diameter independently predict late mortality
irrespective of clinical presentation and may assist in risk stratification.
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Background:Within the context of health care system reform, the cost
efficacy of lower extremity revascularization remains a timely topic. The
effect of an individual patient’s socioeconomic status represents an under-
studied aspect of vascular care, especially with respect to longitudinal costs
and outcomes. The purpose of this study was to examine the relationship
between socioeconomic status and these factors.
Methods: A retrospective femoropopliteal revascularization database,
which included socioeconomic factors (household income, education level,
and payor status), in addition to standard demographic, clinical, anatomic,
and procedural variables, was analyzed during a 3-year period. Patients were
stratified by income level (low income [LI] 200% federal poverty level
[$42,400 for a household of 4], and higher income [HI] 200% federal
poverty level) and revascularization technique (open vs endovascular), and
analyzed for the end points of primary assisted patency, amortized cost per
day of patency, and limb salvage. Data were analyzed with univariate and
multivariate techniques.
Results: A total of 187 patients were identified with complete data for
analysis, 145 in the LI and 41 in theHI cohorts. LI patients differed fromHI
Fig 1. Survival after thoracic endovascular aortic repair is shown
for (A) the study population stratified by white blood cell (WBC)
count 103 cells/mL and 103 cells/mL (P  .01) and (B) for
the subgroup of asymptomatic nonruptured thoracic aneurysms
stratified by WBC count (P  .01)patients by mean age (66.2 1.0 vs 61.8 1.5 years, P .04), high school
graduate rate (51.4% vs 85.4%, P  .001), presence of tissue loss (30.1% vs
